# Optimized Treatment and Regression of HBV-induced Early Cirrhosis

> **NCT01938820** · PHASE4 · COMPLETED · sponsor: **Beijing Friendship Hospital** · enrollment: 82 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** entecavir
- **DRUG:** Thymosin-α

## Key facts

- **NCT ID:** NCT01938820
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938820, "Optimized Treatment and Regression of HBV-induced Early Cirrhosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01938820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*